Journal Information
Statistics
Follow this link to access the full text of the article
Original article
Camrelizumab combined with transcatheter arterial chemoembolization and sorafenib or lenvatinib for unresectable hepatocellular carcinoma: A multicenter, retrospective study
Xiumei Jianga,1, Pan Wangb,c,1, Ke Suc,d,1, Han Lic, Hao Chic, Fei Wange, Yu Liua,
, Ke Xua,
Corresponding author
Corresponding author
a Department of Oncology, Chongqing General Hospital, Chongqing, 401147, China
b Clinical Skills Center, The Affliated Hospital of Southwest Medical University, Luzhou, 646000, China
c Department of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou, 646000, China
d Department of Radiation Oncology, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100000, China
e Department of General Surgery, Luxian People's Hospital, Luzhou, 646100, China